Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 27 of 58, showing 10 Applications out of 576 total, starting on record 261, ending on 270

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

261.

ECCT/21/06/11   Pulse oximeter use in labour
    The use of Fetal Pulse Oximetry in determining fetal wellbeing during labour: A non-randomized clinical trial       
Principal Investigator(s)
1. Felix Mwembi Oindi
Site(s) in Kenya
Aga Khan University hospital
 
10-02-2022 View

262.

ECCT/21/11/08   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Videlis N Nduba
2. Prof. Jessie N Githanga
3. Fredrick Sirwa Chite
4. Bernhards Ragama Ogutu
Site(s) in Kenya
1. KEMRI/CRDR (Nairobi City county)
2. KEMRI Siaya Clinical Research Annex (Siaya county)
3. Gertrude’s Children’s Hospital. (Nairobi City county)
4. Strathmore University Medical Centre (Nairobi City county)
5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
 
02-02-2022 View

263.

ECCT/21/09/02   PrEDIRA - 2
    Piloting HIV Pre-exposure Prophylaxis (PrEP) Integration into Services for Early Pregnancy Loss   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. KEMRI-CCR PHRD THIKA - Thika, Nairobi, Murang\'a, and their environs (Kiambu county)
2. Kisumu clinical trial site - Kisumu and its enrvirons (Kisumu county)
3. Mariestopes - Nairobi (Nairobi City county)
 
23-01-2022 View

264.

ECCT/21/11/01   VAT 00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Walter Godfrey Jaoko
Site(s) in Kenya
1. Kenya Medical Research Institute (Kisumu county)
2. KEMRI/Walter Reed Project Research Center (Kericho county)
3. KEMRI/CCR Partners in Health R&D (PHRD) (Kiambu county)
4. KEMRI CMR (Kisumu county)
5. Kenya Medical Research Institute (Nairobi City county)
6. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
7. Moi University Clinical Research Centre (Uasin Gishu county)
8. Aga Khan University Hospital (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site (Kakamega county)
10. Ganjoni Clinic (Mombasa county)
 
15-01-2022 View

265.

ECCT/21/11/05   SOLIDARITY TRIAL PLUS
    An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care   
Principal Investigator(s)
1. loice Ombajo
Site(s) in Kenya
1. KENYATTA NATIONAL HOSPITAL SITE (Nairobi City county)
2. The Nairobi Hospital (Nairobi City county)
 
13-01-2022 View

266.

ECCT/21/11/04   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Fredrick Sirwa Chite
2. Prof Jessie N Githanga
3. Bernhards Ragama Ogutu
4. Videlis N Nduba
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
21-12-2021 View

267.

ECCT/21/09/03   Women TDF/FTC Benchmark Study
    Pharmacology of TDF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender Women   
Principal Investigator(s)
1. Nelly Mugo
Site(s) in Kenya
KEMRI-CCR PHRD (THIKA) PROJECT
 
19-12-2021 View

268.

ECCT/21/06/14   CoVPN 3008
    Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Kisumu Clinical Research Site (Kisumu county)
 
13-12-2021 View

269.

ECCT/21/08/01   CARES
    Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety,and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa.   
Principal Investigator(s)
1. JOSPHAT KOSGEI
Site(s) in Kenya
1. AMPATH Eldoret (Uasin Gishu county)
2. Aghakhan University (Nairobi City county)
3. Kericho KEMRI WRP CRC site (Kericho county)
 
30-11-2021 View

270.

ECCT/21/06/13   CARES
    A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety,   and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine   From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults   in Sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
3. Aga khan University Hospital (Nairobi City county)
 
18-11-2021 View